Toragen is primarily focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”)
- No safety issues identified in Cohort 1
- Now proceeding to Cohort 2, for which patients have been identified
Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from Cohort 1 of its Phase 1 trial of TGN-S11, its first drug candidate, in patients with HPV-associated cancers.
This Phase 1 trial is an open-label, non-randomized study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The study is being conducted in two parts: a dose escalation part and dose expansion part. The dose escalation consists of five Cohorts of three to six patients. The dose expansion will begin in parallel, if Cohorts 1 and 2 of the escalation part are observed to be safe and well-tolerated and will be one dose level lower than the highest dose observed to be safe and well-tolerated in the dose escalation in combination with a PD-1 checkpoint inhibitor.
“There is a critical unmet medical need for treatments against HPV-associated cancers,” said Dr. Sandra Coufal, Toragen’s CEO. “The current treatments for these cancers are limited and we are thrilled for patients to have Toragen’s clinical trial as an option. Although preliminary, and only Cohort 1, we have seen favorable safety and tolerability data and look forward to continuing to add patients to our trial.”
